Helex is pioneering a paradigm shift in the treatment of chronic and rare kidney disorders by developing programmable non-viral lipid nanoparticle (LNP) therapeutics that deliver therapeutic cargo ...

Helex has raised $3.5m in an oversubscribed seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for kidney diseases. The round saw participation from SOSV, Bluehill ...

Founded in 2021, Helex operates in Health Tech industry. The company focuses on non-viral targeted delivery and genome editing, utilising its proprietary kidney ...

The seed funding round was led by pi Ventures, with participation from a host of investors, including Bluehill.VC, US-based SOSV, among others The startup will deploy the capital to accelerate ...

May 31, 2007 (Seattle, WA) - The pivotal trial of a new device approved for the percutaneous closure of atrial septal defects (ASD)--the HELEX septal occluder (WL Gore and Associates, Flagstaff, ...

Helex, a US and India based therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, today announced its oversubscribed $3.5 million Seed round, led by pi ...